1221 related articles for article (PubMed ID: 12432042)
1. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
Ridker PM; Rifai N; Rose L; Buring JE; Cook NR
N Engl J Med; 2002 Nov; 347(20):1557-65. PubMed ID: 12432042
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
Ridker PM; Hennekens CH; Buring JE; Rifai N
N Engl J Med; 2000 Mar; 342(12):836-43. PubMed ID: 10733371
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms associated with cholesterol and risk of cardiovascular events.
Kathiresan S; Melander O; Anevski D; Guiducci C; Burtt NP; Roos C; Hirschhorn JN; Berglund G; Hedblad B; Groop L; Altshuler DM; Newton-Cheh C; Orho-Melander M
N Engl J Med; 2008 Mar; 358(12):1240-9. PubMed ID: 18354102
[TBL] [Abstract][Full Text] [Related]
5. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory markers and the risk of coronary heart disease in men and women.
Pai JK; Pischon T; Ma J; Manson JE; Hankinson SE; Joshipura K; Curhan GC; Rifai N; Cannuscio CC; Stampfer MJ; Rimm EB
N Engl J Med; 2004 Dec; 351(25):2599-610. PubMed ID: 15602020
[TBL] [Abstract][Full Text] [Related]
7. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
8. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.
Pekkanen J; Linn S; Heiss G; Suchindran CM; Leon A; Rifkind BM; Tyroler HA
N Engl J Med; 1990 Jun; 322(24):1700-7. PubMed ID: 2342536
[TBL] [Abstract][Full Text] [Related]
9. Multiple biomarkers for the prediction of first major cardiovascular events and death.
Wang TJ; Gona P; Larson MG; Tofler GH; Levy D; Newton-Cheh C; Jacques PF; Rifai N; Selhub J; Robins SJ; Benjamin EJ; D'Agostino RB; Vasan RS
N Engl J Med; 2006 Dec; 355(25):2631-9. PubMed ID: 17182988
[TBL] [Abstract][Full Text] [Related]
10. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events.
Albert MA; Glynn RJ; Buring J; Ridker PM
Circulation; 2006 Dec; 114(24):2619-26. PubMed ID: 17116764
[TBL] [Abstract][Full Text] [Related]
11. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
[TBL] [Abstract][Full Text] [Related]
12. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.
Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL;
Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score.
Albert MA; Glynn RJ; Ridker PM
Circulation; 2003 Jul; 108(2):161-5. PubMed ID: 12835213
[TBL] [Abstract][Full Text] [Related]
14. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.
Ridker PM; Cook N
Circulation; 2004 Apr; 109(16):1955-9. PubMed ID: 15051634
[TBL] [Abstract][Full Text] [Related]
16. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
Connelly PW; Stachenko S; MacLean DR; Petrasovits A; Little JA
Can J Cardiol; 1999 Apr; 15(4):419-27. PubMed ID: 10322251
[TBL] [Abstract][Full Text] [Related]
18. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study.
Hadaegh F; Harati H; Ghanbarian A; Azizi F
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):571-7. PubMed ID: 16874147
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
